The site to which the effector binds is termed the allosteric site or regulatory site. Allosteric sites allow effectors to bind to the protein, often resulting in a conformational change and/or a change in protein dynamics. Effectors that enhance the protein's activity are referred to as allosteric activators, whereas those that decrease the protein's activity are called allosteric inhibitors.
Allosteric regulations are a natural example of control loops, such as feedback from downstream products or feedforward from upstream substrates. Long-range allostery is especially important in cell signaling. Allosteric regulation is also particularly important in the cell's ability to adjust enzyme activity.
The term allostery comes from the Ancient Greek allos (ἄλλος), "other", and stereos (στερεός), "solid (object)". This is in reference to the fact that the regulatory site of an allosteric protein is physically distinct from its active site.
Many allosteric effects can be explained by the concerted MWC model put forth by Monod, Wyman, and Changeux, or by the sequential model (also known as the KNF model) described by Koshland, Nemethy, and Filmer. Both postulate that protein subunits exist in one of two conformations, tensed (T) or relaxed (R), and that relaxed subunits bind substrate more readily than those in the tense state. The two models differ most in their assumptions about subunit interaction and the preexistence of both states. For proteins in which subunits exist in more than two conformations, the allostery landscape model described by Cuendet, Weinstein, and LeVine, can be used.
The concerted model of allostery, also referred to as the symmetry model or MWC model, postulates that enzyme subunits are connected in such a way that a conformational change in one subunit is necessarily conferred to all other subunits. Thus, all subunits must exist in the same conformation. The model further holds that, in the absence of any ligand (substrate or otherwise), the equilibrium favors one of the conformational states, T or R. The equilibrium can be shifted to the R or T state through the binding of one ligand (the allosteric effector or ligand) to a site that is different from the active site
The sequential model of allosteric regulation holds that subunits are not connected in such a way that a conformational change in one induces a similar change in the others. Thus, all enzyme subunits do not necessitate the same conformation. Moreover, the sequential model dictates that molecules of a substrate bind via an induced fit protocol. While such an induced fit converts a subunit from the tensed state to relaxed state, it does not propagate the conformational change to adjacent subunits. Instead, substrate-binding at one subunit only slightly alters the structure of other subunits so that their binding sites are more receptive to substrate. To summarize:
- subunits need not exist in the same conformation
- molecules of substrate bind via induced-fit protocol
- conformational changes are not propagated to all subunits
A morpheein is a homo-oligomeric structure that can exist as an ensemble of physiologically significant and functionally different alternate quaternary assemblies. Transitions between alternate morpheein assemblies involve oligomer dissociation, conformational change in the dissociated state, and reassembly to a different oligomer. The required oligomer disassembly step differentiates the morpheein model for allosteric regulation from the classic MWC and KNF models.
Porphobilinogen synthase (PBGS) is the prototype morpheein.
Ensemble models of allosteric regulation enumerate an allosteric system's statistical ensemble as a function of its potential energy function, and then relate specific statistical measurements of allostery to specific energy terms in the energy function (such as an intermolecular salt bridge between two domains). Ensemble models like the ensemble allosteric model and allosteric Ising model assume that each domain of the system can adopt two states similar to the MWC model. The allostery landscape model introduced by Cuendet, Weinstein, and LeVine allows for the domains to have any number of states and the contribution of a specific molecular interaction to a given allosteric coupling can be estimated using a rigorous set of rules. Molecular dynamics simulations can be used to estimate a system's statistical ensemble so that it can be analyzed with the allostery landscape model.
Allosteric modulation is used to alter the activity of molecules and enzymes in biochemistry and pharmacology. For comparison, a typical drug is made to bind to the active site of an enzyme which thus prohibits binding of a substrate to that enzyme causing a decrease in enzyme activity. Allosteric modulation occurs when an effector binds to an allosteric site (also known as a regulatory site) of an enzyme and alters the enzyme activity. Allosteric modulators are designed to fit the allosteric site to cause a conformational change of the enzyme, in particular a change in the shape of the active site, which then causes a change in its activity. In contrast to typical drugs, modulators are not competitive inhibitors. They can be positive (activating) causing an increase of the enzyme activity or negative (inhibiting) causing a decrease of the enzyme activity. The use of allosteric modulation allows the control of the effects of specific enzyme activities; as a result, allosteric modulators are very effective in pharmacology. In a biological system, allosteric modulation can be difficult to distinguish from modulation by substrate presentation.
Energy sensing model
An example of this model is seen with the Mycobacterium tuberculosis, a bacterium that is perfectly suited to adapt to living in the macrophages of humans. The enzyme's sites serve as a communication between different substrates. Specifically between AMP and G6P. Sites like these also serve as a sensing mechanism for the enzyme's performance.
Positive allosteric modulation (also known as allosteric activation) occurs when the binding of one ligand enhances the attraction between substrate molecules and other binding sites. An example is the binding of oxygen molecules to hemoglobin, where oxygen is effectively both the substrate and the effector. The allosteric, or "other", site is the active site of an adjoining protein subunit. The binding of oxygen to one subunit induces a conformational change in that subunit that interacts with the remaining active sites to enhance their oxygen affinity. Another example of allosteric activation is seen in cytosolic IMP-GMP specific 5'-nucleotidase II (cN-II), where the affinity for substrate GMP increases upon GTP binding at the dimer interface.
Negative allosteric modulation (also known as allosteric inhibition) occurs when the binding of one ligand decreases the affinity for substrate at other active sites. For example, when 2,3-BPG binds to an allosteric site on hemoglobin, the affinity for oxygen of all subunits decreases. This is when a regulator is absent from the binding site.
Another example is strychnine, a convulsant poison, which acts as an allosteric inhibitor of the glycine receptor. Glycine is a major post-synaptic inhibitory neurotransmitter in mammalian spinal cord and brain stem. Strychnine acts at a separate binding site on the glycine receptor in an allosteric manner; i.e., its binding lowers the affinity of the glycine receptor for glycine. Thus, strychnine inhibits the action of an inhibitory transmitter, leading to convulsions.
Another instance in which negative allosteric modulation can be seen is between ATP and the enzyme phosphofructokinase within the negative feedback loop that regulates glycolysis. Phosphofructokinase (generally referred to as PFK) is an enzyme that catalyses the third step of glycolysis: the phosphorylation of fructose-6-phosphate into fructose 1,6-bisphosphate. PFK can be allosterically inhibited by high levels of ATP within the cell. When ATP levels are high, ATP will bind to an allosteric site on phosphofructokinase, causing a change in the enzyme's three-dimensional shape. This change causes its affinity for substrate (fructose-6-phosphate and ATP) at the active site to decrease, and the enzyme is deemed inactive. This causes glycolysis to cease when ATP levels are high, thus conserving the body's glucose and maintaining balanced levels of cellular ATP. In this way, ATP serves as a negative allosteric modulator for PFK, despite the fact that it is also a substrate of the enzyme.
A homotropic allosteric modulator is a substrate for its target protein, as well as a regulatory molecule of the protein's activity. It is typically an activator of the protein. For example, O2 and CO are homotropic allosteric modulators of hemoglobin. Likewise, in IMP/GMP specific 5' nucleotidase, binding of one GMP molecule to a single subunit of the tetrameric enzyme leads to increased affinity for GMP by the subsequent subunits as revealed by sigmoidal substrate versus velocity plots.
A heterotropic allosteric modulator is a regulatory molecule that is not the enzyme's substrate. It may be either an activator or an inhibitor of the enzyme. For example, H+, CO2, and 2,3-bisphosphoglycerate are heterotropic allosteric modulators of hemoglobin. Once again, in IMP/GMP specific 5' nucleotidase, binding of GTP molecule at the dimer interface in the tetrameric enzyme leads to increased affinity for substrate GMP at the active site indicating towards K-type heterotropic allosteric activation.
As has been amply highlighted above, some allosteric proteins can be regulated by both their substrates and other molecules. Such proteins are capable of both homotropic and heterotropic interactions.
Some allosteric activators are referred to as "essential", or "obligate" activators, in the sense that in their absence, the activity of their target enzyme activity is very low or negligible, as is the case with N-acetylglutamate's activity on carbamoyl phosphate synthetase I, for example.
A non-regulatory allosteric site is any non-regulatory component of an enzyme (or any protein), that is not itself an amino acid. For instance, many enzymes require sodium binding to ensure proper function. However, the sodium does not necessarily act as a regulatory subunit; the sodium is always present and there are no known biological processes to add/remove sodium to regulate enzyme activity. Non-regulatory allostery could comprise any other ions besides sodium (calcium, magnesium, zinc), as well as other chemicals and possibly vitamins.
Allosteric modulation of a receptor results from the binding of allosteric modulators at a different site (a "regulatory site") from that of the endogenous ligand (an "active site") and enhances or inhibits the effects of the endogenous ligand. Under normal circumstances, it acts by causing a conformational change in a receptor molecule, which results in a change in the binding affinity of the ligand. In this way, an allosteric ligand modulates the receptor's activation by its primary orthosteric ligand, and can be thought to act like a dimmer switch in an electrical circuit, adjusting the intensity of the response.
For example, the GABAA receptor has two active sites that the neurotransmitter gamma-aminobutyric acid (GABA) binds, but also has benzodiazepine and general anaesthetic agent regulatory binding sites. These regulatory sites can each produce positive allosteric modulation, potentiating the activity of GABA. Diazepam is a positive allosteric modulator at the benzodiazepine regulatory site, and its antidote flumazenil is an receptor antagonist.
Allosteric sites as drug targets
Allosteric sites may represent a novel drug target. There are a number of advantages in using allosteric modulators as preferred therapeutic agents over classic orthosteric ligands. For example, G protein-coupled receptor (GPCR) allosteric binding sites have not faced the same evolutionary pressure as orthosteric sites to accommodate an endogenous ligand, so are more diverse. Therefore, greater GPCR selectivity may be obtained by targeting allosteric sites. This is particularly useful for GPCRs where selective orthosteric therapy has been difficult because of sequence conservation of the orthosteric site across receptor subtypes. Also, these modulators have a decreased potential for toxic effects, since modulators with limited co-operativity will have a ceiling level to their effect, irrespective of the administered dose. Another type of pharmacological selectivity that is unique to allosteric modulators is based on co-operativity. An allosteric modulator may display neutral co-operativity with an orthosteric ligand at all subtypes of a given receptor except the subtype of interest, which is termed "absolute subtype selectivity". If an allosteric modulator does not possess appreciable efficacy, it can provide another powerful therapeutic advantage over orthosteric ligands, namely the ability to selectively tune up or down tissue responses only when the endogenous agonist is present. Oligomer-specific small molecule binding sites are drug targets for medically relevant morpheeins.
Synthetic allosteric systems
There are many synthetic compounds containing several noncovalent binding sites, which exhibit conformational changes upon occupation of one site. Cooperativity between single binding contributions in such supramolecular systems is positive if occupation of one binding site enhances the affinity ΔG at a second site, and negative if the affinity isn't highered. Most synthetic allosteric complexes rely on conformational reorganization upon the binding of one effector ligand which then leads to either enhanced or weakened association of second ligand at another binding site. Conformational coupling between several binding sites is in artificial systems usually much larger than in proteins with their usually larger flexibility. The parameter which determines the efficiency (as measured by the ratio of equilibrium constants Krel = KA(E)/KA in presence and absence of an effector E ) is the conformational energy needed to adopt a closed or strained conformation for the binding of a ligand A.
In many multivalent supramolecular systems direct interaction between bound ligands can occur, which can lead to large cooperativities. Most common is such a direct interaction between ions in receptors for ion-pairs. This cooperatitiy is often also referred to as allostery, even though conformational changes here are not necessarily triggering binding events.
Allostery is a direct and efficient means for regulation of biological macromolecule function, produced by the binding of a ligand at an allosteric site topographically distinct from the orthosteric site. Due to the often high receptor selectivity and lower target-based toxicity, allosteric regulation is also expected to play an increasing role in drug discovery and bioengineering. The AlloSteric Database (ASD) provides a central resource for the display, search and analysis of the structure, function and related annotation for allosteric molecules. Currently, ASD contains allosteric proteins from more than 100 species and modulators in three categories (activators, inhibitors, and regulators). Each protein is annotated with detailed description of allostery, biological process and related diseases, and each modulator with binding affinity, physicochemical properties and therapeutic area. Integrating the information of allosteric proteins in ASD should allow the prediction of allostery for unknown proteins, to be followed with experimental validation. In addition, modulators curated in ASD can be used to investigate potential allosteric targets for a query compound, and can help chemists to implement structure modifications for novel allosteric drug design.
Allosteric residues and their prediction
Not all protein residues play equally important roles in allosteric regulation. The identification of residues that are essential to allostery (so-called “allosteric residues”) has been the focus of many studies, especially within the last decade. In part, this growing interest is a result of their general importance in protein science, but also because allosteric residues may be exploited in biomedical contexts. Pharmacologically important proteins with difficult-to-target sites may yield to approaches in which one alternatively targets easier-to-reach residues that are capable of allosterically regulating the primary site of interest. These residues can broadly be classified as surface- and interior-allosteric amino acids. Allosteric sites at the surface generally play regulatory roles that are fundamentally distinct from those within the interior; surface residues may serve as receptors or effector sites in allosteric signal transmission, whereas those within the interior may act to transmit such signals.
- ASD database
- Competitive inhibition
- Cooperative binding
- Enzyme kinetics
- Protein dynamics
- Receptor theory
- Srinivasan B, Forouhar F, Shukla A, Sampangi C, Kulkarni S, Abashidze M, Seetharaman J, Lew S, Mao L, Acton TB, Xiao R, Everett JK, Montelione GT, Tong L, Balaram H (March 2014). "Allosteric regulation and substrate activation in cytosolic nucleotidase II from Legionella pneumophila". The FEBS Journal. 281 (6): 1613–1628. doi:10.1111/febs.12727. PMC 3982195. PMID 24456211.
- Cooper, Alan; Dryden, David (October 1984). "Allostery without conformational change: A plausible model". European Biophysics Journal. 11 (2): 103–109. doi:10.1007/BF00276625. PMID 6544679. S2CID 12591175.
- Liu, Jin; Nussinov, Ruth (2016). "Allostery: An Overview of Its History, Concepts, Methods, and Applications". PLOS Comput. Biol. 12 (6): e1004966. Bibcode:2016PLSCB..12E4966L. doi:10.1371/journal.pcbi.1004966. PMID 27253437. S2CID 3610740.
- Bu Z, Callaway DJ (2011). "Proteins move! Protein dynamics and long-range allostery in cell signaling". Protein Structure and Diseases. Advances in Protein Chemistry and Structural Biology. Vol. 83. pp. 163–221. doi:10.1016/B978-0-12-381262-9.00005-7. ISBN 9780123812629. PMID 21570668.
- Monod J, Wyman J, Changeux JP (May 1965). "On the nature of allosteric transitions:A plausible model". Journal of Molecular Biology. 12: 88–118. doi:10.1016/s0022-2836(65)80285-6. PMID 14343300.
- Koshland DE, Némethy G, Filmer D (January 1966). "Comparison of experimental binding data and theoretical models in proteins containing subunits". Biochemistry. 5 (1): 365–85. doi:10.1021/bi00865a047. PMID 5938952.
- Cuendet MA, Weinstein H, LeVine MV (December 2016). "The Allostery Landscape: Quantifying Thermodynamic Couplings in Biomolecular Systems". Journal of Chemical Theory and Computation. 12 (12): 5758–5767. doi:10.1021/acs.jctc.6b00841. PMC 5156960. PMID 27766843.
- Jaffe EK (September 2005). "Morpheeins--a new structural paradigm for allosteric regulation". Trends in Biochemical Sciences. 30 (9): 490–7. doi:10.1016/j.tibs.2005.07.003. PMID 16023348.
- Motlagh HN, Wrabl JO, Li J, Hilser VJ (April 2014). "The ensemble nature of allostery". Nature. 508 (7496): 331–9. Bibcode:2014Natur.508..331M. doi:10.1038/nature13001. PMC 4224315. PMID 24740064.
- Hilser VJ, Wrabl JO, Motlagh HN (2012). "Structural and energetic basis of allostery". Annual Review of Biophysics. 41: 585–609. doi:10.1146/annurev-biophys-050511-102319. PMC 3935618. PMID 22577828.
- LeVine MV, Weinstein H (May 2015). "AIM for Allostery: Using the Ising Model to Understand Information Processing and Transmission in Allosteric Biomolecular Systems". Entropy. 17 (5): 2895–2918. Bibcode:2015Entrp..17.2895L. doi:10.3390/e17052895. PMC 4652859. PMID 26594108.
- Abdel-Magid AF (February 2015). "Allosteric modulators: an emerging concept in drug discovery". ACS Medicinal Chemistry Letters. 6 (2): 104–7. doi:10.1021/ml5005365. PMC 4329591. PMID 25699154.
- Zhong W, Cui L, Goh BC, Cai Q, Ho P, Chionh YH, Yuan M, Sahili AE, Fothergill-Gilmore LA, Walkinshaw MD, Lescar J, Dedon PC (December 2017). "Allosteric pyruvate kinase-based "logic gate" synergistically senses energy and sugar levels in Mycobacterium tuberculosis". Nature Communications. 8 (1): 1986. Bibcode:2017NatCo...8.1986Z. doi:10.1038/s41467-017-02086-y. PMC 5719368. PMID 29215013.
- Edelstein SJ (1975). "Cooperative interactions of hemoglobin". Annual Review of Biochemistry. 44: 209–32. doi:10.1146/annurev.bi.44.070175.001233. PMID 237460.
- Shi D, Allewell NM, Tuchman M (June 2015). "The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms". International Journal of Molecular Sciences. 16 (6): 13004–22. doi:10.3390/ijms160613004. PMC 4490483. PMID 26068232.
- de Cima S, Polo LM, Díez-Fernández C, Martínez AI, Cervera J, Fita I, Rubio V (November 2015). "Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis". Scientific Reports. 5 (1): 16950. Bibcode:2015NatSR...516950D. doi:10.1038/srep16950. PMC 4655335. PMID 26592762.
- Christopoulos A, May LT, Avlani VA, Sexton PM (November 2004). "G-protein-coupled receptor allosterism: the promise and the problem(s)". Biochemical Society Transactions. 32 (Pt 5): 873–7. doi:10.1042/BST0320873. PMID 15494038.
- May LT, Leach K, Sexton PM, Christopoulos A (2007). "Allosteric modulation of G protein-coupled receptors". Annual Review of Pharmacology and Toxicology. 47: 1–51. doi:10.1146/annurev.pharmtox.47.120505.105159. PMID 17009927.
- Jaffe EK (2010). "Morpheeins – A New Pathway for Allosteric Drug Discovery~!2010-02-12~!2010-05-21~!2010-06-08~!". The Open Conference Proceedings Journal. 1: 1–6. doi:10.2174/2210289201001010001. PMC 3107518. PMID 21643557.
- Takeuchi M, Ikeda M, Sugasaki A, Shinkai S (November 2001). "Molecular design of artificial molecular and ion recognition systems with allosteric guest responses". Accounts of Chemical Research. 34 (11): 865–73. doi:10.1021/ar0000410. PMID 11714258.
- Kremer C, Lützen A (May 2013). "Artificial allosteric receptors". Chemistry. 19 (20): 6162–96. doi:10.1002/chem.201203814. PMID 23463705.
- Kovbasyuk L, Krämer R (June 2004). "Allosteric supramolecular receptors and catalysts". Chemical Reviews. 104 (6): 3161–87. doi:10.1021/cr030673a. PMID 15186190.
- Schneider HJ (September 2016). "Efficiency parameters in artificial allosteric systems". Organic & Biomolecular Chemistry. 14 (34): 7994–8001. doi:10.1039/c6ob01303a. PMID 27431438.
- Badjić JD, Nelson A, Cantrill SJ, Turnbull WB, Stoddart JF (September 2005). "Multivalency and cooperativity in supramolecular chemistry". Accounts of Chemical Research. 38 (9): 723–32. doi:10.1021/ar040223k. PMID 16171315.
- Kim SK, Sessler JL (October 2010). "Ion pair receptors". Chemical Society Reviews. 39 (10): 3784–809. doi:10.1039/c002694h. PMC 3016456. PMID 20737073.
- McConnell AJ, Beer PD (May 2012). "Heteroditopic receptors for ion-pair recognition". Angewandte Chemie. 51 (21): 5052–61. doi:10.1002/anie.201107244. PMID 22419667.
- Huang Z, Zhu L, Cao Y, Wu G, Liu X, Chen Y, Wang Q, Shi T, Zhao Y, Wang Y, Li W, Li Y, Chen H, Chen G, Zhang J (January 2011). "ASD: a comprehensive database of allosteric proteins and modulators". Nucleic Acids Research. 39 (Database issue): D663–9. doi:10.1093/nar/gkq1022. PMC 3013650. PMID 21051350.
- Panjkovich A, Daura X (October 2012). "Exploiting protein flexibility to predict the location of allosteric sites". BMC Bioinformatics. 13: 273. doi:10.1186/1471-2105-13-273. PMC 3562710. PMID 23095452.
- Süel GM, Lockless SW, Wall MA, Ranganathan R (January 2003). "Evolutionarily conserved networks of residues mediate allosteric communication in proteins". Nature Structural Biology. 10 (1): 59–69. doi:10.1038/nsb881. PMID 12483203. S2CID 67749580.
- Mitternacht S, Berezovsky IN (September 2011). "Binding leverage as a molecular basis for allosteric regulation". PLOS Computational Biology. 7 (9): e1002148. Bibcode:2011PLSCB...7E2148M. doi:10.1371/journal.pcbi.1002148. PMC 3174156. PMID 21935347.
- Gasper PM, Fuglestad B, Komives EA, Markwick PR, McCammon JA (December 2012). "Allosteric networks in thrombin distinguish procoagulant vs. anticoagulant activities". Proceedings of the National Academy of Sciences of the United States of America. 109 (52): 21216–22. doi:10.1073/pnas.1218414109. PMC 3535651. PMID 23197839.
- Ghosh A, Vishveshwara S (November 2008). "Variations in clique and community patterns in protein structures during allosteric communication: investigation of dynamically equilibrated structures of methionyl tRNA synthetase complexes". Biochemistry. 47 (44): 11398–407. doi:10.1021/bi8007559. PMID 18842003.
- Sethi A, Eargle J, Black AA, Luthey-Schulten Z (April 2009). "Dynamical networks in tRNA:protein complexes". Proceedings of the National Academy of Sciences of the United States of America. 106 (16): 6620–5. Bibcode:2009PNAS..106.6620S. doi:10.1073/pnas.0810961106. PMC 2672494. PMID 19351898.
- Vanwart AT, Eargle J, Luthey-Schulten Z, Amaro RE (August 2012). "Exploring residue component contributions to dynamical network models of allostery". Journal of Chemical Theory and Computation. 8 (8): 2949–2961. doi:10.1021/ct300377a. PMC 3489502. PMID 23139645.
- Rivalta I, Sultan MM, Lee NS, Manley GA, Loria JP, Batista VS (May 2012). "Allosteric pathways in imidazole glycerol phosphate synthase". Proceedings of the National Academy of Sciences of the United States of America. 109 (22): E1428–36. doi:10.1073/pnas.1120536109. PMC 3365145. PMID 22586084.
- Negre CF, Morzan UN, Hendrickson HP, Pal R, Lisi GP, Loria JP, Rivalta I, Ho J, Batista VS (December 2018). "Eigenvector centrality for characterization of protein allosteric pathways". Proceedings of the National Academy of Sciences of the United States of America. 115 (52): E12201–E12208. arXiv:1706.02327. Bibcode:2018PNAS..11512201N. doi:10.1073/pnas.1810452115. PMC 6310864. PMID 30530700.
- Clarke D, Sethi A, Li S, Kumar S, Chang RW, Chen J, Gerstein M (May 2016). "Identifying Allosteric Hotspots with Dynamics: Application to Inter- and Intra-species Conservation". Structure. 24 (5): 826–837. doi:10.1016/j.str.2016.03.008. PMC 4883016. PMID 27066750.